Upper Tract Urothelial Cancer Resources
Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Sponsored by UroGen Pharma
Upper Tract Urothelial Carcinoma (UTUC) is considered a rare form of cancer and often presents without symptoms. In 2025, it is estimated that there will be approximately 7,000 new cases of UTUC in the United States. Even so, new treatments are regularly explored for this cancer.
Below are resources to help you stay up-to-date with the latest research on UTUC, as well as some helpful patient education materials to help your patients navigate their diagnosis
The Latest in UTUC
AUANews | October 2025
The Future of Vascular-Targeted Photodynamic Therapy in Low-Grade Upper Tract Urothelial Carcinoma
While low-grade disease has a high rate of recurrence, it has a favorable prognosis with a low metastatic potential and morbidity. Therefore, kidney preservation needs to be prioritized in these patients, and tumor ablation is the currently recommended treatment option for low-risk favorable UTUC.
AUANews
AUA Journals
